Analyst Price Targets — GDRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 11:57 am | Eric Sheridan | Goldman Sachs | $3.50 | $2.84 | TheFly | GoodRx price target raised to $3.50 from $2.50 at Goldman Sachs |
| February 26, 2026 6:08 pm | Michael Cherny | Leerink Partners | $3.00 | $2.02 | StreetInsider | GoodRx Holdings Inc. (GDRX) PT Lowered to $3 at Leerink Partners |
| January 22, 2026 6:00 am | Glen Santangelo | Jefferies | $2.75 | $2.58 | StreetInsider | Jefferies Downgrades GoodRx Holdings Inc. (GDRX) to Hold |
| December 18, 2025 12:54 pm | — | Morgan Stanley | $4.00 | $2.78 | TheFly | GoodRx price target lowered to $4 from $5 at Morgan Stanley |
| December 8, 2025 9:14 pm | — | Barclays | $3.00 | $2.72 | TheFly | GoodRx initiated with an Underweight at Barclays |
| August 11, 2025 11:01 am | George Hill | Deutsche Bank | $6.00 | $3.47 | TheFly | GoodRx price target lowered to $6 from $8 at Deutsche Bank |
| June 10, 2024 5:32 am | Craig Hettenbach | Morgan Stanley | $9.50 | $8.55 | TheFly | GoodRx price target raised to $9.50 from $7 at Morgan Stanley |
| May 23, 2024 1:50 am | Mark Mahaney | RBC Capital | $10.00 | $7.20 | StreetInsider | RBC Capital Upgrades GoodRx Holdings Inc. (GDRX) to Outperform |
| May 16, 2024 2:46 pm | Stephanie Davis | Barclays | $9.00 | $8.06 | StreetInsider | Barclays Reiterates Overweight Rating on GoodRx Holdings Inc. (GDRX) |
| May 16, 2024 5:57 am | Aaron Kessler | Raymond James | $10.00 | $7.27 | StreetInsider | Raymond James Upgrades GoodRx Holdings Inc. (GDRX) to Outperform |
Latest News for GDRX
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 5, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 6, 2026 at 5:00 a.m.…
GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors interested in Medical Services stocks are likely familiar with GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched [url="]GoodRx Companion[/url], a new $14.99-per-month subscrip
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GDRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.